Submitted by sandy craine on Wed, 27/03/2013 - 1:30am
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
Massimo Breccia, Giuliana Alimena.
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
Massimo Breccia, Giuliana Alimena.
Submitted by sandy craine on Wed, 27/03/2013 - 1:12am
Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus1, Giuseppe Saglio2, Richard A. Larson3, Dong-Wook Kim4, Gabriel Etienne5, Gianantonio Rosti6, Carmino De Souza7, Mineo Kurokawa8, Matt E. Kalaycio9, Albert Hoenekopp10, Xiaolin Fan11, Yaping Shou11, Hagop M. Kantarjian12, and Timothy P. Hughes13
Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus1, Giuseppe Saglio2, Richard A. Larson3, Dong-Wook Kim4, Gabriel Etienne5, Gianantonio Rosti6, Carmino De Souza7, Mineo Kurokawa8, Matt E. Kalaycio9, Albert Hoenekopp10, Xiaolin Fan11, Yaping Shou11, Hagop M. Kantarjian12, and Timothy P. Hughes13
Submitted by sandy craine on Sat, 23/03/2013 - 12:00pm
21 March 2013
EMA/CHMP/178415/2013 Committee for Medicinal Products for Human Use (CHMP)
Summary of opinion1 (initial authorisation)
Iclusig
Ponatinib
On 21 March 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive
opinion, recommending the granting of a marketing authorisation for the medicinal product Iclusig
15 mg and 45 mg film-coated tablets intended for the treatment of chronic myeloid leukaemia (CML)
and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). Iclusig was
21 March 2013
EMA/CHMP/178415/2013 Committee for Medicinal Products for Human Use (CHMP)
Summary of opinion1 (initial authorisation)
Iclusig
Ponatinib
On 21 March 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive
opinion, recommending the granting of a marketing authorisation for the medicinal product Iclusig
15 mg and 45 mg film-coated tablets intended for the treatment of chronic myeloid leukaemia (CML)
and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). Iclusig was
Submitted by sandy craine on Fri, 15/03/2013 - 6:59pm
Is going for cure in chronic myeloid leukemia possible and justifiable?
Is going for cure in chronic myeloid leukemia possible and justifiable?
Submitted by sandy craine on Fri, 15/03/2013 - 4:59pm
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
Submitted by sandy craine on Thu, 14/03/2013 - 11:28am
CML Stem Cell Burden at Diagnosis Associated With Treatment Outcomes
By Dave Levitan
March 11, 2013
Laboratory studies have suggested that chronic myeloid leukemia (CML) stem cells are resistant to tyrosine kinase inhibitor (TKI) treatment. A new study, though, showed for the first time the effect of stem cell burden on treatment outcome and actually found that TKIs, including imatinib(Drug information on imatinib) and dasatinib(Drug information on dasatinib), can rapidly eradicate most CML stem cells.
CML Stem Cell Burden at Diagnosis Associated With Treatment Outcomes
By Dave Levitan
March 11, 2013
Laboratory studies have suggested that chronic myeloid leukemia (CML) stem cells are resistant to tyrosine kinase inhibitor (TKI) treatment. A new study, though, showed for the first time the effect of stem cell burden on treatment outcome and actually found that TKIs, including imatinib(Drug information on imatinib) and dasatinib(Drug information on dasatinib), can rapidly eradicate most CML stem cells.
Submitted by sandy craine on Wed, 13/03/2013 - 1:12pm
Oncology Enters Era of Genomics: Sledge Calls for Overhaul of Clinical Trials System
Anita T. Shaffer
Oncology Enters Era of Genomics: Sledge Calls for Overhaul of Clinical Trials System
Anita T. Shaffer
Submitted by sandy craine on Sun, 10/03/2013 - 3:11pm
Definitions, methodological and statistical issues for phase 3 clinical trials in
chronic myeloid leukemia: a proposal by the European LeukemiaNet
Joelle Guilhot,1 Michele Baccarani,2 Richard E. Clark,3 Francisco Cervantes,4 Francois Guilhot,1 Andreas Hochhaus,5 Sergei Kulikov,6 Jiri Mayer,7
Definitions, methodological and statistical issues for phase 3 clinical trials in
chronic myeloid leukemia: a proposal by the European LeukemiaNet
Joelle Guilhot,1 Michele Baccarani,2 Richard E. Clark,3 Francisco Cervantes,4 Francois Guilhot,1 Andreas Hochhaus,5 Sergei Kulikov,6 Jiri Mayer,7
Submitted by sandy craine on Sun, 10/03/2013 - 3:03pm
Suboptimal Responses in Chronic Myeloid Leukemia
Elias Jabbour, MD,1 Giuseppe Saglio, MD, PhD,2 Timothy P Hughes, MD,3 and Hagop Kantarjian, MD1
Abstract
The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor prognosis. In 2006, the European LeukemiaNet proposed criteria to identify patients with a suboptimal response to, or failure associated with, imatinib; these recommendations were updated in 2009. Suboptimal responders represent a unique treatment challenge. Although they may respond to continued imatinib therapy, their long-term outcomes may not be as favorable as those for optimally responding patients. Validation studies demonstrated that suboptimal responders are a heterogeneous group, and that the prognostic implications of suboptimal response vary by time point. There are few data derived from clinical trials to guide therapeutic decisions for these patients. Clinical trials are currently underway to assess the efficacy of newer tyrosine kinase inhibitors in this setting. Identification of suboptimal responders or patients failing treatment using hematologic, cytogenetic, and molecular techniques allows physicians to alter therapy earlier in the treatment course to improve long-term outcomes. Cancer 2012;. © 2011 American Cancer Society.
Suboptimal Responses in Chronic Myeloid Leukemia
Elias Jabbour, MD,1 Giuseppe Saglio, MD, PhD,2 Timothy P Hughes, MD,3 and Hagop Kantarjian, MD1
Abstract
The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor prognosis. In 2006, the European LeukemiaNet proposed criteria to identify patients with a suboptimal response to, or failure associated with, imatinib; these recommendations were updated in 2009. Suboptimal responders represent a unique treatment challenge. Although they may respond to continued imatinib therapy, their long-term outcomes may not be as favorable as those for optimally responding patients. Validation studies demonstrated that suboptimal responders are a heterogeneous group, and that the prognostic implications of suboptimal response vary by time point. There are few data derived from clinical trials to guide therapeutic decisions for these patients. Clinical trials are currently underway to assess the efficacy of newer tyrosine kinase inhibitors in this setting. Identification of suboptimal responders or patients failing treatment using hematologic, cytogenetic, and molecular techniques allows physicians to alter therapy earlier in the treatment course to improve long-term outcomes. Cancer 2012;. © 2011 American Cancer Society.
Submitted by sandy craine on Wed, 06/03/2013 - 1:52pm
Susan Branford 1,2
1 Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide,
Australia; and 2 University of Adelaide, Adelaide, Australia
Monitoring response to therapy for patients with chronic myeloid leukemia using an effective strategy is fundamental
for achieving optimal patient outcomes. It will allow the initiation of timely therapeutic intervention for patients with a
Susan Branford 1,2
1 Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide,
Australia; and 2 University of Adelaide, Adelaide, Australia
Monitoring response to therapy for patients with chronic myeloid leukemia using an effective strategy is fundamental
for achieving optimal patient outcomes. It will allow the initiation of timely therapeutic intervention for patients with a
Pages
